US5324571083
US5324571083
Eli Lilly and Company
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 65.179.000.000 | 45.043.000.000 | 44.7% |
| Cost of Revenue | 11.052.000.000 | 8.418.000.000 | 31.3% |
| Gross Profit | 54.127.000.000 | 36.625.000.000 | 47.8% |
| 24.431.000.000 | 19.585.000.000 | 24.7% | |
| Operating Income | 29.696.000.000 | 17.040.000.000 | 74.3% |
| Pretax Income | 25.731.000.000 | 12.680.000.000 | 102.9% |
| Net Income Common Stockholders | 20.640.000.000 | 10.590.000.000 | 94.9% |
| -- | -- | -- | |
| -- | -- | -- |